跳到正文
原文
Nature 健康护理主题·· 12 天前AI 评分55

新冠疫苗接种与感染SARS-CoV-2一年后患者报告健康状况的关系

COVID-19 vaccination and patient-reported health one year after SARS-CoV-2 infection

AI 导读

本研究通过多时点评估了新冠疫苗接种与患者报告健康状况之间的关系。结果显示,接种疫苗在急性期后一年内对患者报告的健康状况影响有限,且调整混杂因素后差异不显著。研究强调了症状定义的PCS与患者报告结果之间的差异,提示未来研究应关注预感染接种以外的其他影响因素。

正文

Introduction

Post-COVID syndrome (PCS) is a heterogeneous condition affecting a substantial proportion of individuals following acute COVID-191. The World Health Organization (WHO) defines PCS as persistent or newly emerging symptoms occurring at least three months after SARS-CoV-2 infection, lasting for a minimum of two months, and not explained by an alternative diagnosis2. Common symptoms include fatigue, cognitive impairment, dyspnea, pain, and psychological distress3. COVID-19 vaccination has been shown to reduce the risk of PCS defined by symptom-based criteria4.

However, these definitions primarily focus on symptom presence and insufficiently capture functional impairment, subjective health status, and health-related quality of life (HRQoL). Consequently, the clinical relevance of vaccination with respect to HRQoL and patient-reported health outcomes remains insufficiently understood. Patient-reported outcome measures (PROMs) are established instruments for assessing patient-perceived health outcomes with previous studies indicating poorer outcomes among patients with PCS5,6.

Early in the COVID-19 pandemic, Germany launched the Network of University Medicine to coordinate national COVID-19 research, within which the National Pandemic Cohort Network (NAPKON) was initiated. NAPKON is a prospective nationwide cohort study comprising three cohorts to comprehensively assess long-term outcomes after COVID-197.

Objectives

This study aimed to evaluate the association between COVID-19 vaccination and patient-perceived health after COVID-19 using validated PROMs covering HRQoL and physical, mental, and cognitive health domains in a prospective nationwide cohort.

Methods

Study population

This study is a retrospective analysis of data derived from a prospectively established cohort. Specifically, we analyzed data from the Cross-Sectoral Platform (SUEP) of NAPKON, which enrolled SARS-CoV-2 positive patients from all healthcare sectors in Germany (university and non-university hospitals, outpatient sector). NAPKON is registered on ClinicalTrials.gov (identifier: NCT04768998).

From July 2020 to May 2023, a total of 2,680 patients had been enrolled in the SUEP cohort. For the present study, we included adult patients (≥ 18 years) with documented vaccination status prior to infection and a valid 3 months follow-up (n = 788). A valid 3-month follow-up required a complete and validated assessment meeting predefined data-quality criteria, including valid information on symptoms and pre-existing condition. Overall, 1,188 participants did not meet these criteria; 133 of them had died before the 3-month follow-up. Patients with implausible vaccination dates (e.g., identical date for first and second dose, n = 31) and those with incomplete vaccination status (single dose; n = 97) were subsequently excluded. To allow sufficient time for immune response maturation, only vaccinations administered ≥ 6 weeks before baseline were considered, reflecting a conservative cut-off given reports of continued immune maturation over several weeks after vaccination8,9. Patients with booster vaccinations within 6 weeks before baseline (n = 13) were therefore classified as 2-dose vaccination. A 14-day cut-off was additionally assessed in a sensitivity analysis (Supplementary Table 1). The final analytic sample comprised 660 patients (Fig. 1).

Patients completed questionnaires at multiple assessments, either in person or by telephone. The questionnaires captured clinical data on the short- and long-term course of COVID-19, PROMs, medical history, and socio-demographics7.

Sequencing data for SARS-CoV-2 variants were available for only a subset of patients (n = 305) and disproportionately reflected Alpha infections. Therefore, missing variant data were imputed based on the predominant circulating variant at the time of infection, as reported in the weekly surveillance reports by Germany’s public health institute (https://public.data.rki.de/t/public/views/IGS_Dashboard/DashboardVOC?%-3Aembed=y&%3AisGuestRedirectFromVizportal=y).

Patient-Reported Outcome Measures (PROMs)

Validated PROMs were used to assess subjective health status. HRQoL was measured using the EuroQol 5-Dimensions 5-Level (EQ-5D-5 l) and EQ-5D Visual Analogue Scale (EQ-5D-VAS)10; anxiety and depression using the Patient Health Questionnaire-4 (PHQ-4)11,12; and cognitive ability using the Patient-Reported Outcomes Measurement Information System (PROMIS) Cognitive Function (short form 4a). Subjective health at a broader level was captured by PROMIS-29 domains (anxiety, depression, fatigue, physical function, pain interference, sleep disturbance, and social participation; excluding pain intensity) and PROMIS Global (mental and physical health). For analysis, raw scores were converted to standardized T-scores (mean = 50, SD = 10) following PROMIS® guidelines (https://www.healthmeasures.net). Published estimates of meaningful within-person change vary by PROM domain and population13; therefore, no universal T-score threshold was applied to between-group differences.

PROMs were analyzed at three time points: end-of-acute COVID-19 (discharge date for inpatients or specific assessment for outpatients as described in the study protocol14, short-term (3 months after baseline, ± 1 month), and long-term (12 months after baseline, ± 1½ months). PROMIS-29 was only available at short- and long-term. Within-person differences (Δ) of PROM scores reflect changes in clinical status at the individual level between time points and were analyzed as described15.

PROMIS cut-points were used to classify results into categorical severity levels and to visualize trajectories across follow-up intervals in Sankey-Diagrams. These visualizations depict individual-level transitions across predefined severity categories over time and capture clinically relevant changes (https://healthmeasures.net/interpret-scores/score-cut-points/). Validated cut-points and complete data across all relevant time points were available only for PROMIS Cognitive Function and PROMIS Global Mental and Physical Health.

Data analysis

Descriptive analyses were reported as mean and standard deviation (SD) for continuous and as absolute and relative frequencies for categorical variables. Group differences were tested using chi-squared test for categorical and one-way analysis of variance (ANOVA) for continuous data, with statistical significance defined as p < 0.05. Missing data were assumed missing at random.

Associations between vaccination status and PROMs were estimated using multivariable linear regression. The primary time point of interest was the 12-month follow-up; analyses across PROM domains and additional time points were exploratory. Covariates for the main model (age, sex, body mass index (BMI), clinical severity during acute COVID-19, imputed virus variant, and Charlson Comorbidity Index (CCI)) were selected based on previous work16. Several sensitivity analyses were performed to assess the robustness of the primary model, including use of a 14-day vaccination cut-off (Supplementary Table 2), combination of all participants with ≥ 2 vaccine doses (Supplementary Table 3), exclusion of acute COVID-19 severity (Supplementary Table 4), and stratification by time since the last vaccination (< 6 vs. ≥ 6 months) (Supplementary Table 5).

Analyses were performed using STATA 19.5 and R 4.5.3.

Ethics statement

This study was conducted in accordance with the principles of the Declaration of Helsinki. All participants provided written informed consent. For the NAPKON-SUEP cohort, primary ethical approval was obtained from the Ethics Committee of the Department of Medicine at Goethe University Frankfurt (approval ID: 20–924). All additional study sites received approval from their respective local ethics committees. Ethical approval for the present study was granted by the Ethics Committee of the University Hospital and Faculty of Medicine of the Eberhard Karls University Tübingen (approval ID: 421/2022BO2).

Results

The study cohort included 660 adults, of whom 380 (57.6%) were male and 560 (85.0%) had been hospitalized for acute COVID-19. Overall, 464 (70.3%) were unvaccinated, 91 (13.8%) were fully vaccinated (2 doses), and 105 (15.9%) were booster vaccinated (≥ 3 doses). PCS, as defined by the WHO, was more frequent in unvaccinated patients (70.7%) than in fully vaccinated (45.6%) or booster vaccinated patients (52.4%). Additional characteristics are shown in Table 1 and Supplementary Table 1.

Table 1 Patient characteristics by vaccination status.

Full size table

Absolute PROM scores

At end-of-acute COVID-19, statistically significant differences between vaccination groups were observed for EQ-5D-VAS (p = 0.001), with higher self-rated health among fully and booster-vaccinated individuals. At short-term, differences between groups were observed for EQ-5D (p = 0.041) and PROMIS Cognitive Function (p = 0.047), with the highest mean EQ-5D scores among fully vaccinated patients and higher mean cognitive scores among both vaccinated groups. At long-term, EQ-5D-VAS scores differed across vaccination groups (p = 0.047), with the highest mean scores observed among fully vaccinated patients (Table 2).

Table 2 PROM scores across different time points stratified by vaccination status.

Full size table

Within-person differences (Δ) of PROM scores over time

Most PROMs improved over time across all groups, with generally greater gains among unvaccinated individuals. Differences were significant for EQ-5D-VAS from end-of-acute COVID-19 to short- (p = 0.005) and long-term (p = 0.007), with greater mean improvements among unvaccinated and fully vaccinated patients. At long-term, overall group differences were also observed for PHQ-4 (p = 0.023) and PROMIS Global Physical Health (p = 0.038), with greater mean improvements among unvaccinated patients. Between short- and long-term, PROMIS-29 Physical Function differed across groups (p = 0.009), again with the greatest mean improvement among unvaccinated patients. In contrast, the overall group difference in PROMIS Cognitive Function at short-term (p = 0.008) reflected a mean improvement among vaccinated patients and a slight mean decline among unvaccinated patients (Table 3).

Table 3 Within-person difference (Δ) of PROM scores between different time points stratified by vaccination status.

Full size table

Multivariable regression results

After adjustment for age, sex, BMI, CCI, imputed virus variant, and clinical severity, EQ-5D-VAS at end-of-acute COVID-19 remained more favorable among booster-vaccinated compared with unvaccinated patients (β = 10.72, 95% CI 1.55 to 19.90). No PROM showed a statistically significant association with vaccination status at short- or long-term follow-up. However, effect directions were largely consistent with the unadjusted findings. As differences were generally small, they should be interpreted cautiously (Table 4). In a sensitivity analysis excluding acute COVID-19 severity from the model, effect directions remained consistent with the primary analysis, with changes limited to statistical significance for selected PROMs and time points (Supplementary Table 4). Further sensitivity analyses yielded results consistent with the primary analysis when using a 14-day vaccination cut-off (Supplementary Table 2) and when combining all participants with ≥ 2 vaccine doses into a single vaccinated group (Supplementary Table 3). When stratifying vaccinated participants by time since the last vaccination (< 6 vs. ≥ 6 months), effect directions remained consistent with the primary analysis (Supplementary Table 5).

Table 4 Adjusted effect of COVID-19 vaccination on PROM scores at time points and on within-person differences (adjusted regression models).

Full size table

After adjustment of the within-person differences (Δ), greater improvement was observed among unvaccinated compared with booster-vaccinated patients for EQ-5D-VAS from end-of-acute to both short- (β = −12.67, 95% CI − 23.98 to − 1.36) and long-term (β = −17.55, 95% CI − 29.85 to − 5.25), for PROMIS Global Physical Health from end-of-acute to short-term (β = −10.95, 95% CI − 21.63 to − 0.27), and for PROMIS Global Mental Health from end-of-acute to long-term (β = −10.89, 95% CI − 20.16 to − 1.61). Overall, effect directions remained largely consistent with the unadjusted analyses, although statistical significance varied across PROMs and time intervals after adjustment (Table 4).

The β-coefficients reported in Table 4 reflect the adjusted association with vaccination status. Estimates for other covariates included in this model, as well as the number of observations and adjusted R² for each model, are provided in supplementary tables 6a-m. Older age, higher BMI, and greater comorbidity burden were predominantly associated with poorer PROM scores and reduced recovery across follow-ups. Women reported lower well-being in absolute scores. Higher acute COVID-19 severity tended to be associated with worse initial PROM scores and larger subsequent improvements. Associations with the imputed SARS-CoV-2 variant varied across PROMs and time points, with Omicron tending toward more favorable, although non-significant, PROM estimates.

Trajectory patterns

Analyses using validated cut-points were restricted to PROMIS Cognitive Function and PROMIS Global Mental and Physical Health. Fully vaccinated (2 doses) and booster-vaccinated individuals (≥ 3 doses) were combined due to limited subgroup sizes, and results are descriptive (Figs. 2, 3, supplementary Fig. 1).

For PROMIS Cognitive Function, cut-point analyses from end-of-acute COVID-19 to short-term showed mainly worsening severity categories among unvaccinated patients, whereas categories most frequently improved among vaccinated patients. These group differences were attenuated when extending the interval to long-term, suggesting greater short-term cognitive recovery among vaccinated patients with converging long-term outcomes.

For PROMIS Global Mental and Physical Health, both groups improved across both intervals. Vaccinated patients improved mainly within higher score categories, whereas unvaccinated individuals predominantly transitioned from lower categories by short-term. Over the longer interval, this pattern reversed, with more upward transitions observed among unvaccinated patients.

Discussion

Findings and interpretation

In this nationwide prospective cohort, vaccination prior to infection was associated with limited, time-dependent, and domain-specific differences in subjective health status and HRQoL following COVID-19. After multivariable adjustment, only EQ-5D-VAS at end-of-acute COVID-19 remained significantly more favorable among booster-vaccinated compared with unvaccinated patients. By 12 months, differences between vaccination groups were small, and no significant associations between vaccination status and PROMs remained after adjustment.

The strong relationship between vaccination status and circulating SARS-CoV-2 variants is important when interpreting our findings. Most vaccinated participants were infected during the Omicron-dominant period, and Omicron infections have been associated with fewer post-acute sequelae than earlier variants17. Although the imputed virus variant showed no consistent independent association with PROMs in the adjusted models, its inclusion attenuated the associations with vaccination status, suggesting that part of the initially observed group differences may reflect pandemic phase and circulating variant rather than vaccination status alone. Accordingly, no significant associations between vaccination status and PROMs remained at three or 12 months after adjustment.

Conversely, unvaccinated participants experienced more severe acute COVID-19, which may have contributed to poorer PROM scores at the end of the acute phase. Greater acute severity has also been associated with poorer subsequent HRQoL18. The larger within-person improvements observed among unvaccinated patients may therefore partly reflect poorer initial PROM scores related to greater acute disease burden, leaving greater potential for recovery. However, as the within-person change analyses were intended as complementary exploratory analyses, they should not be interpreted as causal effects. Time since vaccination may further modify post-COVID outcomes, with recent studies suggesting greater protection when vaccination occurred closer to infection19,20. This is consistent with the well-described waning of vaccine protection against SARS-CoV-2 infection over time21,22. In our sensitivity analysis stratified by < 6 versus ≥ 6 months since the last vaccination, effect directions remained consistent with the primary analysis.

Comparison with existing literature

Our findings are consistent with evidence that vaccination reduces severe acute COVID-19 and the risk of symptom-defined PCS4. However, evidence on patient-reported outcomes remains limited and heterogeneous. An Israeli study reported slightly higher EQ-5D scores among individuals vaccinated before infection, with small effects that attenuated over time and were no longer detectable beyond 12 months23. Other studies have also reported more favorable patient-reported outcomes among vaccinated or boosted individuals, including better 6-month EQ-5D scores in a small Omicron-era outpatient PCS cohort24, faster EQ-5D-based recovery in a large single-center UK PCS cohort infected mainly before Omicron25, and better long-term PROMIS physical and mental health scores with a dose-dependent pattern in an analysis of the INSPIRE registry26.

Overall, direct comparisons are limited by substantial methodological differences, including vaccination definitions, follow-up duration, outcome measures, restriction to PCS cohorts, and survey-based data collection in some studies. Evidence on PROMs beyond EQ-5D remains particularly sparse. By assessing multiple validated PROM domains in SARS-CoV-2-infected patients irrespective of post-acute sequelae, our study extends previous work and provides a broader patient-centered perspective on vaccination-related differences in post-COVID recovery.

Clinical implications and future research

Clinically, our findings highlight the need to distinguish symptom-defined PCS from PROM-based functional impairment. A recent analysis of the same NAPKON cohort showed vaccination-related differences across PCS case definitions and phenotypes based on symptom presence16. In contrast, the present study indicates that these symptom-based differences are not consistently associated with clinically relevant long-term differences in PROM-based subjective health status. Thus, PCS definition based on symptom presence alone may insufficiently capture clinical severity, functional burden, and patient-perceived recovery. Our findings therefore support the complementary use of PROMs alongside symptom-based definitions in post-COVID research and clinical care.

Our findings have implications for immunization policy and clinical care. Although vaccination is associated with reduced symptom-defined PCS, this does not necessarily translate into sustained improvements in patient-perceived health, functional recovery, or HRQoL. Vaccination strategies should continue to focus on preventing severe acute disease while incorporating patient-centered post-COVID outcomes into evaluation and surveillance. Clinically, persistent post-COVID limitations require structured assessment that extends beyond symptom burden alone and includes measures of functional impairment, including PROMs. This may help identify individuals with ongoing impairments and guide personalized management strategies.

Future studies should validate these findings in larger cohorts with sufficient power for vaccination subgroups. They should account for vaccine type, number of doses, timing before infection, virus variant, reinfections, antiviral treatment, and pre-infection health status.

Strengths and limitations

Strengths of this study include the nationwide prospective cohort design, early enrollment after SARS-CoV-2 detection, one-year follow-up, and the use of multiple validated PROMs. The combination of absolute scores, within-person differences, and severity-category trajectories provides a broad patient-centered perspective on recovery after COVID-19.

Several limitations should be considered. First, the observational design precludes causal inference. Second, the high proportion of hospitalized patients (85%) limits generalizability, particularly to milder infections. Third, pre-COVID PROM values were unavailable, so individual health-loss attributable to SARS-CoV-2 infection could not be determined. Fourth, vaccine type, exact timing, and PCR-confirmed variant information were incomplete; SARS-CoV-2 variants were therefore imputed based on the dominant circulating variant at the time of infection, introducing potential misclassification. Fifth, although PROMs are appropriate for capturing patient-centered outcomes, they are self-reported and may be influenced by expectations and reporting behavior. Sixth, despite multivariable adjustment, residual confounding by unmeasured factors cannot be excluded, particularly given differences in baseline characteristics between vaccination groups, including age, comorbidity burden, and acute disease severity. Finally, some subgroup and cut-point analyses were based on small sizes and should be interpreted as exploratory. Given the exploratory analyses and the large number of comparisons, the risk of type I error is increased; individual statistically significant findings should therefore be interpreted cautiously.

Conclusions

Overall, vaccination status was associated with only limited differences in patient-reported health after COVID-19, and no significant associations remained at 3 or 12 months after multivariable adjustment. The discrepancy between symptom-defined PCS and patient-reported outcomes suggests that symptom counts alone may not fully capture clinical severity and functional impairment. Future research should identify modifiable determinants of post-COVID recovery beyond pre-infection vaccination.

Fig. 1

Flowchart study population.

Fig. 2

Transitionsa in PROMIS Cognitive Function and PROMIS Global Mental and Physical Health from end-of-acute COVID-19 to long-term for unvaccinated and vaccinated patients. a Categories based on validated PROMIS cutpoints; see https://healthmeasures.net/interpret-scores/score-cut-points/ for details.

Fig. 3

Transitionsa in PROMIS Cognitive Function and PROMIS Global Mental and Physical Health from end-of-acute COVID-19 to short-term for unvaccinated and vaccinated patients. a Categories based on validated PROMIS cutpoints; see https://healthmeasures.net/interpret-scores/score-cut-points/ for details.

Data availability

The data analyzed in this study are not publicly available; access may be granted for scientifically justified research purposes upon submission of a formal data-use-application and approval by the NAPKON Use and Access Commitee, subject to the applicable ethical, legal, and data-protection requirements.

References

  1. Greenhalgh, T., Sivan, M., Perlowski, A. & Nikolich, J. Ž. Long COVID: a clinical update. Lancet 404 (10453), 707–724 (2024).

    Article  CAS  PubMed  Google Scholar 

  2. Soriano, J. B., Murthy, S., Marshall, J. C., Relan, P. & Diaz, J. V. Condition WHOCCDWGoP-C-. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 22 (4), e102–e7 (2022).

    Article  CAS  PubMed  Google Scholar 

  3. Geng, L. N. et al. 2024 update of the RECOVER-adult long COVID research index. JAMA 333 (8), 694–700 (2024).

    Article  Google Scholar 

  4. Green, R., Marjenberg, Z., Banerjee, H. L. G. Y., Wisnivesky, A. & Delaney, J. A systematic review and meta-analysis of the impact of vaccination on prevention of long COVID. Nat. Commun. 16 (1), 10326 (2025).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Carlile, O. et al. Impact of long COVID on health-related quality-of-life: an OpenSAFELY population cohort study using patient-reported outcome measures (OpenPROMPT). The Lancet Regional Health - Europe (2024).

  6. Gottlieb, M. et al. Severe fatigue and persistent symptoms at 3 months following severe acute respiratory syndrome coronavirus 2 infections during the pre-delta, delta, and omicron time periods: a multicenter prospective cohort study. Clin. Infect. Dis. 76 (11), 1930–1941 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Schons, M. et al. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics. Eur. J. Epidemiol. 37 (8), 849–870 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ward, H. et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat. Commun. 13 (1), 907 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Yuan, Y. et al. Characteristics of humoral and cellular responses to coronavirus disease 2019 (COVID-19) inactivated vaccine in central China: a prospective, multicenter, longitudinal study. Front. Immunol. 14, 1107866 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ludwig, K., Graf von der Schulenburg, J-M. & Greiner, W. German value Set for the EQ-5D-5L. PharmacoEconomics 36, 663–674 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Kroenke, K., Spitzer, R. L., Williams, J. B. W. & Löwe, B. An ultra-brief screening scale for anxiety and depression: the PHQ-4. Psychosomatics 50 (6), 613–621 (2009).

    PubMed  Google Scholar 

  12. Löwe, B. et al. A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHG-4) in the general population. J. Affect. Disord. 122, 86–95 (2009).

    Article  PubMed  Google Scholar 

  13. Terwee, C. B. et al. Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures. Qual. Life Res. 30 (10), 2729–2754 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  14. NAPKON. Visitenübersicht in Napkon. Version 2.0. In NAPKON, editor.: NAPKON (2021).

  15. Wisk, L. E. et al. Association of initial SARS-CoV-2 test positivity with patient-reported well-being 3 months after a symptomatic illness. JAMA Netw. Open. 5 (12), 1–15 (2022).

    Article  Google Scholar 

  16. Kraus, T. et al. Impact of COVID-19 vaccination on post-COVID syndrome across clinical definitions and phenotypes: a prospective multicenter cohort study. Mayo Clinic Proc. 2026, 1–20 (2026).

  17. Peter, R. S. et al. Population-based comparison of post-acute sequelae of COVID-19 and health-related quality of life across pandemic periods: Omicron era versus early pandemic. Sci. Rep. 16, 1 (2026).

  18. Verveen, A. et al. Health-related quality of life among persons with initial mild, moderate, and severe or critical COVID-19 at 1 and 12 months after infection: a prospective cohort study. BMC Med. 20 (1), 422 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  19. Kim, S. A., Maeda, M., Murata, F. & Fukuda, H. Effect of COVID-19 vaccination on the risk of developing post-COVID conditions: the VENUS study. Vaccine 43 (Pt 2), 126497 (2025).

    Article  PubMed  Google Scholar 

  20. Smid, M. et al. Post-vaccination, post-infection and hybrid immunity against severe cases of COVID-19 and long COVID after infection with SARS-CoV-2 Omicron subvariants, Czechia, December 2021 to August 2023. Euro. Surveill. ;29, 35 (2024).

  21. Nordstrom, P., Ballin, M. & Nordstrom, A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet 399 (10327), 814–823 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  22. Ssentongo, P. et al. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. BMC Infect. Dis. 22 (1), 439 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kuodi, P. et al. Association between BNT162b2 vaccination and reported incidence of post-COVID-19 symptoms: cross-sectional study 2020-21, Israel. NPJ Vaccines. 7 (1), 101 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Di Fusco, M. et al. Impact of COVID-19 and effects of booster vaccination with BNT162b2 on six-month long COVID symptoms, quality of life, work productivity and activity impairment during Omicron. J. Patient Rep. Outcomes. 7 (1), 77 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  25. Prashar, J. et al. Trajectory, healthcare utilisation and recovery in 3590 individuals with long covid: a 4-year prospective cohort analysis. BMJ Open. 16 (1), e103884 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  26. Gottlieb, M. et al. Differences in Long COVID severity by duration of illness, symptom evolution, and vaccination: a longitudinal cohort study from the INSPIRE group. Lancet Reg. Health – Americas. 44, 1–11 (2025).

    Google Scholar 

  27. Charlson, M. E., Pompei, P., Ales, K. L. & MacKenzie, C. R. A new method of classifying prognostic comorbidity in longitudinal studies: development andvalidation. J. Chronic Dis. 40 (5), 373–383 (1987).

    Article  CAS  PubMed  Google Scholar 

  28. World Health Organization. A clinical casedefinition of post COVID-19 condition by a Delphi consensus. (2021).

Download references

Acknowledgements

We gratefully thank all NAPKON sites who contributed patient data and/or biosamples for this analysis. The representatives of NAPKON sites contributing at least 5 per mille to this analysis are (alphabetical order): Bielefeld University, Medical School and University Medical Center OWL, Bielefeld (Alsaad K, Hamelmann E, Heidenreich H, Hornberg C, Kulamadayil-Heidenreich NSA, Maasjosthusmann P, Muna A, Ruwe M, Stellbrink C, Tebbe J), Medical Faculty of the Otto von Guericke University Magdeburg (Obst W, Kaasch A, Keitel V, Marquardt P, Butzmann J), Practice for general medicine Dashti, Eberswalde (Dashti H, Dashti Y, Tessmer C), Practice for general medicine Egestorf Bispingen, Bispingen (Laumerich B), Practice for general medicine Tennental, Deckenpfronn (Silberbaur I), University Hospital Augsburg, Augsburg (Bader S, Engelmann M, Fuchs A, Langer A, Maerkl B, Messmann H, Muzalyova A, Roemmele C), University Hospital Carl Gustav Carus, Dresden (Altmann H, Berner R, Dressen S, Koch T, Lindemann D, Seele K, Spieth P, Tausche K, Toepfner N, v. Bonin S), University Hospital Duesseldorf, Duesseldorf (de Angelis C, Feldt T, Feuerhake ML, Jensen BEO, Killer A, Luedde T, Lutterbeck M, Paluschinski M, Timm J, Ventura-Pereira J), University Hospital Erlangen, Erlangen (Kraska D, Kremer AE, Leppkes M, Mang J, Neurath MF, Prokosch HU, Schmid J, Vetter M, Willam C, Wolf K), University Hospital Frankfurt, Frankfurt am Main (Bellinghausen C, Cremer S, Groh A, Gruenewaldt A, Khodamoradi Y, Klinsing S, Rohde G, Vehreschild M, Arendt C, Vogl T), University Hospital Hamburg-Eppendorf, Hamburg (Addo M, Almahfoud M, Engels ALF, Jarczak D, Kerinn M, Kluge S, Kobbe R, Petereit S, Schlesner C, Zeller T), University Hospital Leipzig, Leipzig (Baber R, Bercker S, Krug N, Mueller SD, Wirtz H), University Hospital Muenster, Muenster (Boeckel G, Meier JA, Nowacki T, Tepasse PR, Vollenberg R, Wilms C), University Hospital Regensburg, Regensburg (Albig H, Burkhardt R, Feustel M, Fisser C, Hansch S, Hanses F, Hitzenbichler F, Niedermair T, Schuster P, Tran T), University Hospital RWTH Aachen, Aachen (Dahl E, Dreher M, Marx N, Mueller-Wieland D, Wipperfuerth J), University Hospital Schleswig-Holstein Kiel, Kiel (Cleef S, Friedrichs A, Kujat C, Pape D, Schunk D), University Hospital Schleswig-Holstein Luebeck, Luebeck (Kaeding N, Nissen M, Rupp J), University Hospital Technical University Munich, Munich (Barkey W, Erber J, Fricke L , Gladis S, Michler T, Mueller L, Schneider J, Spinner C, Winter C), University Hospital Tuebingen, Tuebingen (Bitzer M, Bunk S, Goepel S, Haeberle H, Kienzle K, Mahrhofer H, Malek N, Rosenberger P, Struemper C, Trauner F), University Hospital Wuerzburg, Wuerzburg (Einsele H, Frantz S, Frey A, Haas K, Haertel C, Herrmann J, Meybohm P, Schmidt J, Schulze P, Volkmann J), University Hospitals of the Ruhr University Bochum, Bochum (Brinkmann F, Brueggemann Y, Gambichler T, Hellwig K, Luecke T, Reinacher-Schick A, Schmidt WE, Schuette C, Steinmann E, Torres Reyes C), University Medical Center Goettingen, Central Biobank, Goettingen (Nussbeck SY), University Medical Center Goettingen, Central Laboratory, Goettingen (Hafke A), University Medical Center Goettingen, Emergency Department, Goettingen (Blaschke S, Hermanns G, Santibanez-Santana M, Zeh S), University Medicine Essen, Essen (Brochhagen L, Dolff S, Elsner C, Krawczyk A, Madel RJ, Otte M, Thuemmler L, Witzke O), University Medicine Greifswald, Greifswald (Becker K, Doerr M, Lehnert K, Nauck M, Piasta N, Schaefer C, Schaefer E, Schattschneider M, Scheer C, Stahl D), University Medicine Oldenburg, Oldenburg (Arlt A, Griesinger F, Guenther U, Hamprecht A, Juergens K, Kluge A, Meinhardt C, Meinhardt K, Petersmann A, Prenzel R).We gratefully thank all participating NAPKON and NUKLEUS infrastructures that contributed to this analysis. The representatives of these NAPKON and NUKLEUS infrastructures are (alphabetical order): Charite - Universitaetsmedizin Berlin, Berlin (Lorbeer R, Schaller J), Helmholtz Center Munich, Munich (Kraus M, Lorenz-Depiereux B), University Hospital Frankfurt, Frankfurt (Appel K, Brechtel M, Broehl I, Fiedler K, Geisler R, Hopff SM, Knaub K, Lee C, Nunes de Miranda S, Raquib S, Sauer G, Scherer M, Vehreschild JJ, Wagner P, Wolf L), University Hospital Wuerzburg, Wuerzburg (Guenther K, Haug F, Haug J), University Hospital Wuerzburg and University of Wuerzburg, Wuerzburg (Fiessler C, Heuschmann PU, Miljukov O, Nuernberger C, Reese JP, Schmidbauer L), University Medicine Goettingen, Goettingen (Chaplinskaya I, Hanss S, Krefting D, Pape C, Rainers M, Schoneberg A, Weinert N), University Medicine Greifswald, Greifswald (Bahls T, Hoffmann W, Nauck M, Schaefer C, Schattschneider M, Stahl D, Valentin H), University of Wuerzburg, Wuerzburg (Jiru-Hillmann S).We gratefully thank the NAPKON Steering Committee: University Hospital Giessen and Marburg, Giessen (Herold S), University of Würzburg, Würzburg (Heuschmann P), Charité - Universitätsmedizin Berlin, Berlin (Heyder R), University Medicine Greifswald, Greifswald (Hoffmann W), Hannover Unified Biobank, Hannover Medical School, Hannover (Illig T), University Hospital Schleswig-Holstein, Kiel (Schreiber S), University Hospital Cologne and University Hospital Frankfurt, Cologne and Frankfurt (Vehreschild JJ), Charité - Universitätsmedizin Berlin, Berlin (Witzenrath M).

Funding

Open Access funding enabled and organized by Projekt DEAL. The project National Pandemic Cohort Network (NAPKON) is part of the Network of University Medicine (NUM), funded by the German Federal Ministry of Research, Technology and Space (BMFTR) (FKZ: 01KX2524).

Author information

Author notes

  1. A list of authors and their affiliations appears at the end of the paper.

Authors and Affiliations

  1. Institute of General Practice and Interprofessional Care, University Hospital Tübingen, Osianderstrasse 5, 72076, Tübingen, Germany

    Christian Förster, Stefanie Joos & Tanja Kraus

  2. Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Institute of General Practice and Family Medicine, Charitéplatz 1, 10117, Berlin, Germany

    Hendrik Napierala

  3. Institute for General Practice, Faculty of Medicine, Leipzig University, Leipzig, Germany

    Anne Schrimpf

  4. Emergency Department, University Medical Center, Göttingen, Germany

    Sabine Blaschke

  5. Department for Infection Control and Infectious Diseases, University Hospital Regensburg, Regensburg, Germany

    Frank Hanses

  6. Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany

    Raja Idris

  7. Department of Pediatrics, Children’s Center Bethel, University Hospital OWL, University Bielefeld, Bielefeld, Germany

    Eckard Hamelmann & Jeremy Schmidt

  8. Department of Anesthesia, Intensive Care Medicine, Emergency Medicine and Pain Medicine, University Medicine Greifswald, Greifswald, Germany

    Christian S. Scheer

  9. Internal Medicine III – Gastroenterology and Infectious Diseases, University Hospital of Augsburg, Augsburg-Kriegshaber, Germany

    Christoph Römmele

  10. Department of Medicine 1, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany

    Marcel Vetter

  11. Department of internal Medicine 1, University Hospital Tübingen, Tübingen, Germany

    Siri Göpel

  12. 1st Department of Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Maher Almahfoud

  13. RWTH cBMB at the Institute of Pathology, Medical Faculty of RWTH Aachen University, Aachen, Germany

    Edgar Dahl

  14. Institute of Medical Microbiology and Virology, Carl von Ossietzky University Oldenburg, Oldenburg, Germany

    Axel Hamprecht

  15. Department of Internal Medicine I, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

    Anette Friedrichs

  16. Institute of Medical Microbiology and Hospital Hygiene, Medical Faculty of the Otto von Guericke University Magdeburg, Magdeburg, Germany

    Jana Butzmann

  17. TUM School of Medicine, Clinical Department for Internal Medicine II, TUM University Hospital, Munich, Germany

    Johanna Erber

  18. University Children’s Hospital, Ruhr University Bochum, Bochum, Germany

    Thomas Lücke

  19. Institute for Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany

    Julia Wendel, Carolin Nürnberger & Jens-Peter Reese

  20. Institute for medical Data Sciences, University Hospital Würzburg, Würzburg, Germany

    Julia Wendel & Carolin Nürnberger

  21. Department of Gastroenterology, Hepatology and Infectious Diseases, Düsseldorf University Hospital, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany

    Björn-Erik Ole Jensen

  22. Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, Munster, Germany

    Phil-Robin Tepasse

  23. Practice for General Medicine Dashti, Eberswalde, Germany

    Hiwa Dashti

  24. Institute for Digital Medicine and Clinical Data Sciences, Faculty of Medicine, Goethe University Frankfurt, Frankfurt, Germany

    J. Janne Vehreschild, Margarete Scherer, Isabel Bröhl, Shimita Raquib, Katharina S. Appel & Ramsia Geisler

  25. Department I of Internal Medicine, Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, Duesseldorf, Germany

    Lazar Mitrov

  26. University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany

    Lazar Mitrov

  27. Technische Hochschule Mittelhessen (THM), Faculty of Health, University of Applied Science, Giessen, Germany

    Jens-Peter Reese

  28. Hannover Unified Biobank, Hannover Medical School, Hannover, Germany

    Thomas Illig

  29. Department of Medical Informatics, University Medical Center, Göttingen, Germany

    Dagmar Krefting

Authors

  1. Christian Förster
  2. Hendrik Napierala
  3. Anne Schrimpf
  4. Stefanie Joos
  5. Sabine Blaschke
  6. Frank Hanses
  7. Raja Idris
  8. Eckard Hamelmann
  9. Jeremy Schmidt
  10. Christian S. Scheer
  11. Christoph Römmele
  12. Marcel Vetter
  13. Siri Göpel
  14. Maher Almahfoud
  15. Edgar Dahl
  16. Axel Hamprecht
  17. Anette Friedrichs
  18. Jana Butzmann
  19. Johanna Erber
  20. Thomas Lücke
  21. Julia Wendel
  22. Björn-Erik Ole Jensen
  23. Phil-Robin Tepasse
  24. Hiwa Dashti
  25. J. Janne Vehreschild
  26. Margarete Scherer
  27. Lazar Mitrov
  28. Isabel Bröhl
  29. Shimita Raquib
  30. Carolin Nürnberger
  31. Jens-Peter Reese
  32. Katharina S. Appel
  33. Ramsia Geisler
  34. Thomas Illig
  35. Dagmar Krefting
  36. Tanja Kraus

Consortia

the NAPKON Study Group

  • Christian Förster
  • , Hendrik Napierala
  • , Anne Schrimpf
  • , Stefanie Joos
  • , Sabine Blaschke
  • , Frank Hanses
  • , Raja Idris
  • , Eckard Hamelmann
  • , Jeremy Schmidt
  • , Christian S. Scheer
  • , Christoph Römmele
  • , Marcel Vetter
  • , Siri Göpel
  • , Maher Almahfoud
  • , Edgar Dahl
  • , Axel Hamprecht
  • , Anette Friedrichs
  • , Jana Butzmann
  • , Johanna Erber
  • , Thomas Lücke
  • , Julia Wendel
  • , Björn-Erik Ole Jensen
  • , Phil-Robin Tepasse
  • , Hiwa Dashti
  • , J. Janne Vehreschild
  • , Margarete Scherer
  • , Lazar Mitrov
  • , Isabel Bröhl
  • , Shimita Raquib
  • , Carolin Nürnberger
  • , Jens-Peter Reese
  • , Katharina S. Appel
  • , Ramsia Geisler
  • , Thomas Illig
  • , Dagmar Krefting
  •  & Tanja Kraus

Contributions

C.F. wrote the manuscript and interpreted the data; T.K. performed the statistical analysis and wrote the manuscript; H.N. and A.S. contributed to drafting the manuscript; S.J. was involved in the conception of the study; all authors critically reviewed and approved the final version of the manuscript.

Corresponding author

Correspondence to Christian Förster.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

For the NAPKON-SUEP cohort, primary ethical approval was obtained from the Ethics Committee of the Department of Medicine at Goethe University Frankfurt (approval ID: 20–924). All additional study sites received approval from their respective local ethics committees. Ethical approval for the present study was granted by the Ethics Committee of the University Hospital and Faculty of Medicine of the Eberhard Karls University Tübingen (approval ID: 421/2022BO2).

Consent for publication

Not applicable.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Förster, C., Napierala, H., Schrimpf, A. et al. COVID-19 vaccination and patient-reported health one year after SARS-CoV-2 infection. Sci Rep 16, 37409 (2026). https://doi.org/10.1038/s41598-026-78285-9

Download citation

  • Received: 19 August 2026

  • Accepted: 26 October 2026

  • Published: 09 November 2026

  • Version of record: 09 November 2026

  • DOI: https://doi.org/10.1038/s41598-026-78285-9

Keywords

来源:Nature 健康护理主题 · nature.com